Many prevalent CNS conditions now have cost effective options after lots of breakthroughs in the 90s and 00s. Increasingly now the focus in CNS is on niche populations in prevalent diseases or rare conditions. This is where developers believe that can make the most difference, ultimately offering meaningful difference to patients and value to payors. Adelphi Real World has responded to this in their data collection strategy. New data sets have now been captured in >10 rare CNS conditions with many more planned and samples in more prevalent conditions are being targeted at populations with poor control, such as Progressive Multiple Sclerosis, Treatment Resistant Depression, and Motor Complications in Parkinson’s Disease. One hugely prevalent area where little progress had been made to date is Alzheimer’s disease but that is all now set to change with a series of treatments about to become available. With 25 years of historic data and new data now available ARW are well poised to understand the impact of some of the most anticipated treatment launches this century.

Many pain related conditions have experienced setbacks in the development of novel drugs that will offer physicians additional options to help provide efficacy once patients progress to moderate or severe levels of pain. The opioid epidemic has only compounded the need for safer, alternative, efficacious options. One area that is thriving, however, is migraine. A rush of approvals in the last couple of years for new classes of drugs with specific migraine indications has led to this area becoming one of the more dynamic conditions. The need now is to understand how these new options are revolutionising the treatment landscape, which patients are receiving certain options and why and what is impact on patient outcomes? Data from the pain portfolio of Disease Specific Programmes can demonstrate the high level of unmet need that exists in conditions such as osteoarthritis, perceptions from patients and physicians about opioids and can help demonstrate the treatment landscape and subsequent impact to patients in areas that have experienced great evolution in recent years, such as migraine.